Alder BioPharmaceuticals Announces Closing of $250M of 2.50% Convertible Senior Notes Due 2025 Post author:Sam Post published:February 1, 2018 Post category:BioPharma Alder intends to use the cash to fund the development and commercialization of eptinezumab. Source: BioSpace You Might Also Like Torrent Pharma Coughs Up $558M for Unichem's India Biz November 2, 2017 Edwards Lifesciences Gets Split Decision In UK Heart Valve Patent Spat With Boston Scientific March 2, 2017 Watch Out! Novartis AG Hungry for Small Takeover Targets With Early-Stage Drugs January 24, 2017
Edwards Lifesciences Gets Split Decision In UK Heart Valve Patent Spat With Boston Scientific March 2, 2017